Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
On February 4, 2022 10 AM ET, Global Liver Institute led an Externally-Led Patient-Focused Drug Development Meeting (EL-PFDD) on Primary Biliary Cholangitis (PBC). This online event is open to the...
Donna R. Cryer, JD, President and CEO, Honored with Awards from the American Association for the Study of Liver Diseases (AASLD) and Global Genes for leadership in connecting, empowering, inspiring...
POLICY PERSPECTIVE The liver advocacy community — with the GLI Liver Action Network leading the way — has elevated patient voices through a variety of initiatives throughout September and October....
Fatty liver disease (FLD) and nonalcoholic steatohepatitis (NASH) are increasing in prevalence worldwide, creating a major global public health crisis. To adequately educate patients, practitioners,...
Dear Colleague: October is Liver Cancer Awareness Month. This represents an opportunity to draw attention to the global burden of liver cancer and to highlight the various public health...
(Washington, DC, Friday, October 22, 2021)—Global Liver Institute (GLI) CEO and President, Donna R. Cryer, JD, yesterday applauded the actions of U.S. Representative Nydia Velázquez...
POLICY PERSPECTIVE Liver diseases affect a wide range of people spanning a plethora of ages, genders, socio-economic statuses, and ethnicities. To ensure this diverse population is represented, it...
The Global Liver Institute (GLI) has been consistent, since March 2020, in advocating for the prioritization of liver patients, cancer patients, transplant recipients, and those with compromised...
(Washington, D.C., Friday, August 13, 2021)—Global Liver Institute (GLI) CEO and President Donna R. Cryer, JD, today applauded dual actions from U.S. government health agencies: U.S. Food and Drug...
Recent News
Let’s Ensure Access to Treatment for PBC Patients - Pediatric & Rare Liver Diseases NewsAmplifying the rare liver disease voice for PBC patients during our monthly policy call Global Liver Institute’s August Pediatric and Rare Liver Diseases monthly...
Understanding the New EASL-EASD-EASO Guidelines on MASLD New Clinical Practice Guidelines for MASLD, developed jointly by EASL, EASD, and EASO, update the 2016 guidelines to reflect recent advancements. They focus on early identification and intervention and the...
Global Liver Institute Welcomes Larry R. Holden as CEO(Washington, D.C., September 3, 2024) – The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the organization’s Chief Executive...
More Than a Cure, a Path to Improvement: Hepatitis C TreatmentHepatitis C infection, an infection of the liver by the hepatitis C virus, is a major global health concern, affecting millions. Although the liver itself does not have pain receptors, the inflammation due...
Understanding the New EASL-EASD-EASO Guidelines on MASLDWho are EASL, EASD, EASO? EASL, EASD, and EASO are prominent European organizations in the field of health and medicine, each focusing on a specific area: The European Association for the Study of the Liver...
